摘要
目的探讨胃癌合并幽门螺杆菌感染CYP2C19基因型与其预后的关系。方法选取我院2017年1月~2018年12月收治的胃癌合并Hp感染患者100例,作为观察组,另选取同期胃癌无合并Hp感染患者100例作为对照组,检测两组患者的CYP2C19基因型,并通过通过电话、复诊等方式对所有患者随访2年,记录其生存情况,依据是否生存分为死亡组和生存组,采用单因素分析法分析CYP2C19的基因多态性对胃癌患者Hp感染及预后的影响,对有统计学差异的基因型进一步采用Logistic分析法筛选其中危险基因型。结果两组患者在纯合子快代谢型及杂合子快代谢型分布比例比较无统计学差异(P>0.05)观察组慢代谢型基因型比例显著高于对照组(P<0.05);慢代谢基因型胃癌患者死亡率显著高于另外两种基因型患者(P<0.001),而纯合子快代谢基因型与杂合子快代谢基因型间死亡率比较无统计学差异(P>0.05)。结论胃癌合并幽门螺杆菌感染患者中CYP2C19慢代谢型基因表达较高,且慢代谢型CYP2C19胃癌患者预后相对较差。
Objective To explore the relationship between CYP2C19 genotype andprognosis of patients with gastric cancer combined with helicobacter pylori infection.Methods 100 patients with gastric cancer combined with Hp infection who were admitted to our hospital from January 2017 to December 2018 were selected as the observation group.Another 100 patients with gastric cancer without Hp infection were selected as the control group.The CYP2C19 genotype was detected.All patients were followed up for 2 years by telephone and subsequent visit,and survival conditions were recorded.According to the status of survival,they were divided into the death group and the survival group.Univariate analysis was performed to analyze the effect of CYP2C19 gene polymorphism on Hp infection and prognosis of patients with gastric cancer.Logistic analysis was performed to screen the risk genotypes from those with statistical differences.Results There was no significant difference in the distribution proportion of homozygous extensive metabolizers and heterozygote extensive metabolizers between the two groups(P>0.05).The proportion of poor metabolizers in the observation group was significantly higher than that in the control group(P<0.05).The mortality rate of gastric cancer patients with poor metabolizers was significantly higher than that of patients with the other two genotypes(P<0.001).There was no significant difference in themortality rate between homozygous extensive metabolizers and heterozygote extensive metabolizers(P>0.05).Conclusion Theexpression of CYP2C19 poor metabolizer genotypes is relatively higher in patients with gastric cancer and Hp infection.The prognosis of gastric cancer patients with CYP2C19 poor metabolizer genotypes is relatively worse.
作者
佟铁刚
张日来
冯瑞兴
TONG Tiegang;ZHANG Rilai;FENG Ruixing(Fourth Department of Internal Medicine,Beijiao Hospital,Shunde District,Foshan,Guangdong,Foshan 528311,China;Department of Emergency,Beijiao Hospital,Shunde District,Foshan,Guangdong,Foshan 528311,China)
出处
《中国医药科学》
2019年第19期203-205,212,共4页
China Medicine And Pharmacy
基金
广东省佛山市卫生和计划生育局医学科研项目（20170284）
